| Literature DB >> 14739666 |
G Varuni Kondagunta1, Jennifer Bacik, Lawrence Schwartz, Joel Sheinfeld, Dean Bajorin, Jacqueline Vuky, Stephanie Marion, Madhu Mazumdar, George J Bosl, Robert J Motzer.
Abstract
Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.Entities:
Mesh：
Substances：
Year: 2004 PMID： 14739666 DOI： 10.1023/B:DRUG.0000011794.21608.59
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850